Versant Capital Management, Inc Avidity Biosciences, Inc. Transaction History
Versant Capital Management, Inc
- $454 Million
- Q4 2024
A detailed history of Versant Capital Management, Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 269 shares of RNA stock, worth $8,204. This represents 0.0% of its overall portfolio holdings.
Number of Shares
269
Previous 296
9.12%
Holding current value
$8,204
Previous $13,000
46.15%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$324 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$281 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$263 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$248 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$214 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.59B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...